Bristol-Myers Squibb Stock
Bristol-Myers Squibb Stock
Bristol-Myers Squibb gained 0.470% compared to yesterday.
Our community is currently high on Bristol-Myers Squibb with 6 Buy predictions and 3 Sell predictions.
With a target price of 61 € there is a positive potential of 35.59% for Bristol-Myers Squibb compared to the current price of 44.99 €.
Our community identified positive and negative aspects for Bristol-Myers Squibb stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Bristol-Myers Squibb stock. On the other hand our users think that "Business model" could be a problem in the future.
Pros and Cons of Bristol-Myers Squibb in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bristol-Myers Squibb vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | 0.470% | 1.507% | -0.011% | -18.434% | -3.491% | -14.346% | -0.940% |
| Johnson & Johnson | -0.410% | 0.013% | 3.457% | -1.566% | 5.664% | 6.552% | 26.561% |
| Elanco Animal Health Inc. | -1.330% | -0.850% | -1.597% | 18.297% | -3.402% | -52.733% | - |
| Biogen Inc. | 0.870% | -1.550% | -2.867% | -24.958% | -24.576% | -30.487% | -16.561% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
When evaluating the financials of Bristol-Myers Squibb Company (symbol: BMY), the impression is that the company embodies a complex but compelling pharmaceutical player characterized by both strengths and challenges. While the balance sheets, cash flow statements, and income statements showcase a robust revenue-generating ability, several underlying factors such as profitability ratios and market performance warrant further scrutiny.
In order to provide clarity on Bristol-Myers’ financial health, it is necessary to explore the various pros and cons that define its current financial position.
*Pros: *
Comments
Bristol-Myers Squibb (NYSE: BMY) had its price target raised by analysts at Barclays PLC from $41.00 to $42.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Bank of America Co. from $72.00 to $68.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $81.00 to $69.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat